325 related articles for article (PubMed ID: 30338648)
21. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
22. Total glucosides of paeony alleviates experimental Sjögren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells.
Jiang T; Guo J; Wang Y; Wu H; Chen Y; Wang S; Zhang H; Long Q; Yao G
Clin Exp Rheumatol; 2023 Dec; 41(12):2502-2510. PubMed ID: 38149512
[TBL] [Abstract][Full Text] [Related]
23. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
24. SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1/STAT3 pathway in primary Sjögren's syndrome.
Hu P; Cai J; Yang C; Xu L; Ma S; Song H; Yang P
Int Immunopharmacol; 2024 Jan; 126():111282. PubMed ID: 38061117
[TBL] [Abstract][Full Text] [Related]
25. Increased frequency of CCR7
Wu C; Yang P; Liu H; Xiao W; Zhao L
Cytokine; 2018 Oct; 110():9-17. PubMed ID: 29684636
[TBL] [Abstract][Full Text] [Related]
26. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
27. The PD-1 with PD-L1 Axis Is Pertinent with the Immune Modulation of Atrial Fibrillation by Regulating T Cell Excitation and Promoting the Secretion of Inflammatory Factors.
Chang G; Chen Y; Liu Z; Wang Y; Ge W; Kang Y; Guo S
J Immunol Res; 2022; 2022():3647817. PubMed ID: 35600045
[TBL] [Abstract][Full Text] [Related]
28. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
29. The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19
Wang Z; Tan F
Scand J Immunol; 2020 Feb; 91(2):e12836. PubMed ID: 31598989
[TBL] [Abstract][Full Text] [Related]
30. Total glucosides of paeony suppresses experimental autoimmune uveitis in association with inhibition of Th1 and Th2 cell function in mice.
Huang XT; Wang B; Zhang WH; Peng MQ; Lin D
Int J Immunopathol Pharmacol; 2018; 32():394632017751547. PubMed ID: 29363368
[TBL] [Abstract][Full Text] [Related]
31. The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.
Sthoeger Z; Sharabi A; Asher I; Zinger H; Segal R; Shearer G; Elkayam O; Mozes E
Clin Immunol; 2018 Jul; 192():85-91. PubMed ID: 29730433
[TBL] [Abstract][Full Text] [Related]
32. Blockade of Th17 response by IL-38 in primary Sjögren's syndrome.
Luo D; Chen Y; Zhou N; Li T; Wang H
Mol Immunol; 2020 Nov; 127():107-111. PubMed ID: 32950755
[TBL] [Abstract][Full Text] [Related]
33. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.
Zhao Y; Jia Y; Li C; Shao R; Fang Y
Shock; 2019 Mar; 51(3):289-297. PubMed ID: 29702526
[TBL] [Abstract][Full Text] [Related]
34. Catalpol ameliorates Sjögren's Syndrome by modulating interplay of T and B cells.
Lin R; Hao D; Dong Y; Wang Y
Biomed Pharmacother; 2020 Mar; 123():109806. PubMed ID: 31951976
[TBL] [Abstract][Full Text] [Related]
35. Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis.
Cai L; Zhang C; Wu J; Zhou W; Chen T
Clin Immunol; 2021 Aug; 229():108800. PubMed ID: 34289424
[TBL] [Abstract][Full Text] [Related]
36. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome.
Miao M; Hao Z; Guo Y; Zhang X; Zhang S; Luo J; Zhao X; Zhang C; Liu X; Wu X; Xu D; Zhao J; Lu X; Gao C; Li X
Ann Rheum Dis; 2018 Dec; 77(12):1838-1840. PubMed ID: 29936436
[No Abstract] [Full Text] [Related]
37. Expression of programmed cell death-1 and its ligand B7 homolog 1 in peripheral blood lymphocytes from patients with peripartum cardiomyopathy.
Xia G; Zheng X; Yao X; Yao X; Liu Z; Wang J
Clin Cardiol; 2017 May; 40(5):307-313. PubMed ID: 28026044
[TBL] [Abstract][Full Text] [Related]
38. Impaired Interleukin-27-Mediated Control of CD4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjögren's Syndrome.
Lucchesi D; Coleby R; Pontarini E; Prediletto E; Rivellese F; Hill DG; Derrac Soria A; Jones SA; Humphreys IR; Sutcliffe N; Tappuni AR; Pitzalis C; Jones GW; Bombardieri M
Arthritis Rheumatol; 2020 Sep; 72(9):1559-1570. PubMed ID: 32307922
[TBL] [Abstract][Full Text] [Related]
39. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
40. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
